Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Protective effects of the neuropeptide PACAP in diabetic retinopathy

Protective effects of the neuropeptide PACAP in diabetic retinopathy Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with highly potent neurotrophic and neuroprotective effects. PACAP and its receptors occur in the retina and PACAP has been applied in animal models of metabolic retinal disorders to reduce structural and functional damage. Furthermore, PACAP has been implicated as a potential anti-diabetic peptide. Our aim has been to investigate, by using a complex morphological, immunochemical and molecular biological approach, whether PACAP attenuates diabetic retinopathy. Diabetes was induced in rats with a single streptozotocin injection. PACAP was injected intravitreally into one eye (100 pmol) three times during the last week of a 3-week survival period. Retinas were processed for the following procedures: routine histology, immunohistochemistry (single and double labeling, whole-mount), quantitative reverse transcription with the polymerase chain reaction and Western blotting. Cone photoreceptors and dopaminergic amacrine and ganglion cells degenerated in diabetic retinas and glial fibrillary acidic protein were upregulated in Müller glial cells. The number of cones, the length of their outer segments and the cell number in the ganglion cell layer were decreased. PACAP ameliorated these structural changes. Moreover, PACAP increased the levels of PAC1-receptor and tyrosine-hydroxylase as detected by molecular biological methods. Thus, PACAP has significant protective effects in the diabetic retina. PACAP treatment attenuates neuronal cell loss in diabetic retinopathy, the protective effects of PACAP probably being mediated through the activation of PAC1-receptor. These results suggest that PACAP has a therapeutic potential in diabetic retinopathy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cell and Tissue Research Springer Journals

Protective effects of the neuropeptide PACAP in diabetic retinopathy

Download PDF
10 pages
Read Article

Loading next page...
 
/lp/springer-journals/protective-effects-of-the-neuropeptide-pacap-in-diabetic-retinopathy-hsNnq2aT7J
Publisher
Springer Journals
Copyright
Copyright © 2012 by Springer-Verlag
Subject
Biomedicine; Human Genetics; Molecular Medicine; Proteomics
ISSN
0302-766X
eISSN
1432-0878
DOI
10.1007/s00441-012-1349-0
pmid
22350850
Publisher site
See Article on Publisher Site

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with highly potent neurotrophic and neuroprotective effects. PACAP and its receptors occur in the retina and PACAP has been applied in animal models of metabolic retinal disorders to reduce structural and functional damage. Furthermore, PACAP has been implicated as a potential anti-diabetic peptide. Our aim has been to investigate, by using a complex morphological, immunochemical and molecular biological approach, whether PACAP attenuates diabetic retinopathy. Diabetes was induced in rats with a single streptozotocin injection. PACAP was injected intravitreally into one eye (100 pmol) three times during the last week of a 3-week survival period. Retinas were processed for the following procedures: routine histology, immunohistochemistry (single and double labeling, whole-mount), quantitative reverse transcription with the polymerase chain reaction and Western blotting. Cone photoreceptors and dopaminergic amacrine and ganglion cells degenerated in diabetic retinas and glial fibrillary acidic protein were upregulated in Müller glial cells. The number of cones, the length of their outer segments and the cell number in the ganglion cell layer were decreased. PACAP ameliorated these structural changes. Moreover, PACAP increased the levels of PAC1-receptor and tyrosine-hydroxylase as detected by molecular biological methods. Thus, PACAP has significant protective effects in the diabetic retina. PACAP treatment attenuates neuronal cell loss in diabetic retinopathy, the protective effects of PACAP probably being mediated through the activation of PAC1-receptor. These results suggest that PACAP has a therapeutic potential in diabetic retinopathy.

Journal

Cell and Tissue Research – Springer Journals

Published: Feb 17, 2012

References

  • Predominant cone photoreceptor dysfunction in a hyperglycaemic model of non-proliferative diabetic retinopathy
    Alvarez, Y; Chen, K; Reynolds, AL; Waghorne, N; O'Connor, JJ; Kennedy, BN
  • Review of pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects
    Atlasz, T; Szabadfi, K; Kiss, P; Racz, B; Gallyas, F; Tamas, A; Gaal, V; Marton, Z; Gabriel, R; Reglodi, D
  • Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin
    Barber, AJ; Lieth, E; Khin, SA; Antonetti, DA; Buchanan, AG; Gardner, TW
  • The possible role of retinal dopaminergic system in visual performance
    Brandies, R; Yehuda, S
  • Identification and characterization of tyrosine hydroxylase immunoreactive amacrine cells
    Brecha, NC; Oyster, CW; Takahashi, ES
  • Light regulation of retinal dopamine that is independent of melanopsin phototransduction
    Cameron, MA; Pozdeyev, N; Vugler, AA; Cooper, H; Iuvone, PM; Lucas, RJ
  • Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells
    Castorina, A; Giunta, S; Mazzone, V; Cardile, V; D'Agata, V
  • The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy
    Dickinson, T; Mitchell, R; Robberecht, P; Fleetwood-Walker, SM
  • Retinopathy in animal models of diabetes
    Engerman, RL; Kern, TS
  • Effect of tyrosine administration on dopa accumulation in light- and dark-adapted retinas from normal and diabetic rats
    Fernstrom, MH; Volk, EA; Fernstrom, JD; Iuvone, PM
  • Diabetic retinopathy
    Fong, DS; Aiello, LP; Ferris, FL; Klein, R
  • Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas
    Gastinger, MJ; Singh, RS; Barber, AJ
  • Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita diabetic mice
    Gastinger, MJ; Kunselman, AR; Conboy, EE; Bronson, SK; Barber, AJ
  • Control of dopamine release in the retina: a transgenic approach to neural networks
    Gustincich, S; Feigenspan, A; Wu, DK; Koopman, LJ; Raviola, E
  • Evidence for photoreceptor changes in patients with diabetic retinopathy
    Holopigian, K; Greenstein, VC; Seiple, W; Hood, DC; Carr, RE
  • The major cell populations of the mouse retina
    Jeon, CJ; Strettoi, E; Masland, RH
  • The prevalence of diabetic retinopathy among adults in the United States
    Kempen, JH; O’Colmain, BJ; Leske, MC; Haffner, SM; Klein, R; Moss, SE; Taylor, HR; Hamman, RF
  • Hyperoxia, hyperglycemia, and photoreceptor sensitivity in normal and diabetic subjects
    Kurtenbach, A; Mayser, HM; Jägle, H; Fritsche, A; Zrenner, E
  • Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases
    Li, M; Maderdrut, JL; Lertora, JJ; Arimura, A; Batuman, V
  • Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy
    Lieth, E; Barber, AJ; Xu, B; Dice, C; Ratz, MJ; Tanase, D; Strother, JM
  • Suppressors of cytokine-signaling proteins induce insulin resistance in the retina and promote survival of retinal cells
    Liu, X; Mameza, MG; Lee, YS; Eseonu, CI; Yu, CR; Kang Derwent, JJ; Egwuagu, CE
  • Extreme diversity among amacrine cells: implications for function
    MacNeil, MA; Masland, RH
  • Management of diabetic retinopathy. A systematic review
    Mohamed, Q; Gillies, MC; Wong, TY
  • Alterations in the retinal dopaminergic neuronal system in rats with streptozotocin-induced diabetes
    Nishimura, C; Kuriyama, K
  • Dopamine-stimulated adenylate cyclase and tyrosine hydroxylase in diabetic rat retina
    Northington, FK; Hamill, RW; Banerjee, SP
  • Up-regulated expression of neuronal nitric oxide synthase in experimental diabetic retina
    Park, JW; Park, SJ; Park, SH; Kim, KY; Chung, JW; Chun, MH; Oh, SJ
  • Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina
    Park, SH; Park, JW; Park, SJ; Kim, KY; Chung, JW; Chun, MH; Oh, SJ
  • Paired-flash identification of rod and cone dysfunction in the diabetic rat
    Phipps, JA; Fletcher, EL; Vingrys, AJ
  • Diabetogenic effect of streptozotocin in the rat during the perinatal period
    Portha, B; Levacher, C; Picon, L; Rosselin, G
  • The neuroprotective effects of PACAP in monosodium glutamate-induced retinal lesion involve inhibition of proapoptotic signaling pathways
    Racz, B; Gallyas, F; Kiss, P; Toth, G; Hegyi, O; Gasz, B; Borsiczky, B; Ferencz, A; Roth, E; Tamas, A; Lengvari, I; Lubics, A; Reglodi, D
  • Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells
    Seki, M; Tanaka, T; Nawa, H; Usui, T; Fukuchi, T; Ikeda, K; Abe, H; Takei, N
  • Pigment epithelium derived factor as an anti-inflammatory factor against decrease of glutamine synthetase expression in retinal Müller cells under high glucose conditions
    Shen, X; Zhong, Y; Xie, B; Cheng, Y; Jiao, Q
  • Electrical responses from diabetic retina
    Shirao, Y; Kawasaki, K
  • Topical administration of adrenergic receptor pharmaceutics and nerve growth factor
    Steinle, JJ
  • The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas
    Szkudelski, T
  • Effects of pituitary adenylate cyclase activating polypeptide in retinal degeneration induced by monosodium-glutamate
    Tamas, A; Gabriel, R; Racz, B; Denes, V; Kiss, P; Lubics, A; Lengvari, I; Reglodi, D
  • Application of encapsulated cell technology for retinal degenerative diseases
    Tao, W
  • The organization of dopaminergic neurons in vertebrate retinas
    Witkovsky, P; Schutte, M
  • Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes
    Yamamoto, K; Hashimoto, H; Tomimoto, S; Shintani, N; Miyazaki, J; Tashiro, F; Aihara, H; Nammo, T; Li, M; Yamagata, K; Miyagawa, J; Matsuzawa, Y; Kawabata, Y; Fukuyama, Y; Koga, K; Mori, W; Tanaka, K; Matsuda, T; Baba, A
  • Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats
    Zeng, XX; Ng, YK; Ling, EA

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

Sign up
for free
Start 14 day
Free Trial